Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Phase II Study of Combining Cabozantinib and Atezolizumab as the 1st Line Therapy for PD-L1 Negative Advanced/Metastatic NSCLC (Cabatezo-1)

NCT05859217 is registered in ClinicalTrials.gov with Jun Zhang, MD, PhD as lead sponsor.

NCT NCT05859217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05859217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Phase II Study of Combining Cabozantinib and Atezolizumab as the 1st Line Therapy for PD-L1 Negative Advanced/Metastatic NSCLC (Cabatezo-1)
Lead sponsor
Jun Zhang, MD, PhD
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2024
Completion date
June 30, 2028
Enrollment
40 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced nsclc, lung cancer, metastatic nsclc - non-small cell lung cancer, nsclc stage iv